DCF Advisers LLC Buys 25,250 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

Key Points

• DCF Advisers LLC increased its stake in Zai Lab by 39%, acquiring an additional 25,250 shares, bringing their total ownership to 90,000 shares.
• Multiple institutional investors have significantly increased their holdings in Zai Lab, with FMR LLC leading by boosting its stake by 749.1% in the last quarter.
• Analysts have mixed views on Zai Lab, with a consensus rating of "Moderate Buy" and an average price target of $54.28, despite recent downgrades from certain firms.

DCF Advisers LLC boosted its stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 39.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 90,000 shares of the company's stock after buying an additional 25,250 shares during the period. Zai Lab makes up about 1.6% of DCF Advisers LLC's investment portfolio, making the stock its 20th largest holding. DCF Advisers LLC owned 0.08% of Zai Lab worth $3,253,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. FMR LLC increased its holdings in shares of Zai Lab by 749.1% in the 4th quarter. FMR LLC now owns 5,475,505 shares of the company's stock worth $143,403,000 after purchasing an additional 4,830,646 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Zai Lab by 63.6% in the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock worth $104,257,000 after purchasing an additional 1,121,856 shares in the last quarter. RTW Investments LP bought a new stake in shares of Zai Lab in the 4th quarter worth $65,714,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Zai Lab by 30.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,354,025 shares of the company's stock worth $61,653,000 after purchasing an additional 548,378 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Zai Lab by 46,222.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock worth $77,058,000 after purchasing an additional 2,127,598 shares in the last quarter. Institutional investors own 41.65% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on ZLAB. Leerink Partners set a $75.00 target price on Zai Lab and gave the stock an "outperform" rating in a report on Monday, June 30th. Wall Street Zen downgraded Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $54.28.

Zai Lab Price Performance

ZLAB stock opened at $36.82 on Friday. The company has a market cap of $4.09 billion, a P/E ratio of -14.79 and a beta of 1.03. Zai Lab Limited Unsponsored ADR has a 1 year low of $16.01 and a 1 year high of $44.34. The stock's fifty day moving average price is $36.01 and its 200-day moving average price is $32.87.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. The firm had revenue of $106.49 million for the quarter, compared to the consensus estimate of $118.40 million. Zai Lab had a negative return on equity of 33.35% and a negative net margin of 60.26%. As a group, analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Insider Activity at Zai Lab

In related news, CFO Yajing Chen sold 9,618 shares of Zai Lab stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $30.00, for a total transaction of $288,540.00. Following the transaction, the chief financial officer directly owned 17,429 shares in the company, valued at approximately $522,870. The trade was a 35.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William Lis sold 13,814 shares of Zai Lab stock in a transaction on Friday, June 20th. The shares were sold at an average price of $35.67, for a total value of $492,745.38. Following the transaction, the director owned 35,106 shares in the company, valued at $1,252,231.02. This trade represents a 28.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 160,155 shares of company stock worth $4,959,535. Corporate insiders own 4.96% of the company's stock.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.